State of Wisconsin Investment Board bought a new position in shares of Fortress Biotech, Inc. (NASDAQ:FBIO) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 25,000 shares of the biopharmaceutical company’s stock, valued at approximately $119,000.

Other hedge funds have also recently added to or reduced their stakes in the company. ClariVest Asset Management LLC increased its stake in shares of Fortress Biotech by 1.0% during the first quarter. ClariVest Asset Management LLC now owns 161,519 shares of the biopharmaceutical company’s stock worth $598,000 after buying an additional 1,600 shares during the period. Geode Capital Management LLC increased its stake in shares of Fortress Biotech by 3.2% during the first quarter. Geode Capital Management LLC now owns 288,566 shares of the biopharmaceutical company’s stock worth $1,067,000 after buying an additional 8,958 shares during the period. KCG Holdings Inc. purchased a new stake in shares of Fortress Biotech during the first quarter worth approximately $188,000. Bank of New York Mellon Corp increased its stake in shares of Fortress Biotech by 4.9% during the first quarter. Bank of New York Mellon Corp now owns 110,061 shares of the biopharmaceutical company’s stock worth $408,000 after buying an additional 5,170 shares during the period. Finally, Rhumbline Advisers increased its stake in shares of Fortress Biotech by 2.8% during the second quarter. Rhumbline Advisers now owns 38,846 shares of the biopharmaceutical company’s stock worth $185,000 after buying an additional 1,075 shares during the period. Hedge funds and other institutional investors own 11.99% of the company’s stock.

Fortress Biotech, Inc. (NASDAQ:FBIO) opened at 4.48 on Friday. The stock’s market capitalization is $226.36 million. The firm has a 50-day moving average of $4.44 and a 200 day moving average of $4.09. Fortress Biotech, Inc. has a 52 week low of $1.88 and a 52 week high of $5.13.

A number of analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Fortress Biotech from a “hold” rating to a “sell” rating in a research note on Tuesday, September 12th. FBR & Co restated a “buy” rating on shares of Fortress Biotech in a research note on Tuesday, July 4th. HC Wainwright set a $11.00 target price on shares of Fortress Biotech and gave the stock a “buy” rating in a research note on Tuesday, July 11th. Rodman & Renshaw assumed coverage on shares of Fortress Biotech in a research note on Tuesday, July 11th. They set a “buy” rating and a $11.00 target price on the stock. Finally, ValuEngine upgraded shares of Fortress Biotech from a “sell” rating to a “hold” rating in a research note on Wednesday, June 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $9.67.

COPYRIGHT VIOLATION NOTICE: “State of Wisconsin Investment Board Buys New Position in Fortress Biotech, Inc. (FBIO)” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/09/17/state-of-wisconsin-investment-board-buys-new-position-in-fortress-biotech-inc-fbio.html.

Fortress Biotech Company Profile

Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.

Institutional Ownership by Quarter for Fortress Biotech (NASDAQ:FBIO)

Receive News & Ratings for Fortress Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.